疾病修饰疗法临床试验设计和帕金森病治疗终点的演变
Tom Foltynie1, Sonia Gandhi1,2, Camille Carroll3
1Department of Clinical & Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
Journal of Parkinson's disease
|February 9, 2026
概括
传统的临床试验没有发现对帕金森病 (PD) 的疾病修饰治疗方法. 本综述探讨了试验设计中的挑战,并提出了改善发现有效PD疗法的解决方案.
科学领域:
- 神经科学是一个神经科学.
- 临床试验 临床试验
- 药理学 药理学是指药理学的学科.
背景情况:
- 传统的双盲,安慰剂对照试验证实了帕金森病 (PD) 的症状缓解,但未能确定改变疾病的治疗方法.
- 关键的挑战包括对PD病理生理学的不完全理解,药物输送问题以及疾病的显著异质性.
- 疾病进展缓慢以及对结果测量和生物标志物缺乏共识,进一步使试验设计复杂化.
研究的目的:
- 审查目前帕金森病临床试验设计的局限性.
- 讨论阻碍鉴定PD疾病修饰治疗的挑战.
- 为不断发展的临床试验设计提出方法,以提高发现PD疗法的成功率.
主要方法:
- 对帕金森病现有临床试验方法的文献综述.
- 分析导致过去试验在识别疾病修饰剂方面失败的因素.
- 讨论试验设计的潜在改进,包括目标选择,剂量和结果措施.
主要成果:
- 目前的试验设计不足以检测帕金森病中的疾病修饰.
- 对PD病理生理学和疾病异质性的不充分理解是主要障碍.
- 缺乏标准化的结果测量和可靠的生物标志物阻碍了进展.
结论:
- 发展临床试验设计对于推进帕金森病研究至关重要.
- 解决试验设计挑战可以增加发现PD疾病修饰治疗的可能性.
- 未来的研究应该集中在针对帕金森病复杂性的创新试验策略上.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...


